Literature DB >> 12774294

Enantioseparation of racemic 4-aryl-3,4-dihydro-2(1H)-pyrimidones on chiral stationary phases based on 3,5-dimethylanilides of N-(4-alkylamino-3,5-dinitro)benzoyl L-alpha-amino acids.

Darko Kontrec1, Vladimir Vinković, Vitomir Sunjić, Birgit Schuiki, Walter M F Fabian, C Oliver Kappe.   

Abstract

Three novel chiral packing materials for high-performance liquid chromatography were prepared by covalently binding of (2S)-N-(3,5-dimethylphenyl)-2-[(4-chloro-3,5-dinitrophenyl)carbonylamino]propan-amide (7), (2S)-N-(3,5-dimethylphenyl)-2-[(4-chloro-3,5-dinitrophenyl)carbonylamino]-4-methylpentanamide (8), and (2S)-N-(3,5-dimethylphenyl)-2-[(4-chloro-3,5-dinitrophenyl)carbonyl-amino]-2-phenylacetamide (9) to aminopropyl silica. The resulting chiral stationary phases (CSPs 1-3) proved effective for the resolution of racemic 4-aryl-3,4-dihydro-2(1H)-pyrimidone derivatives (TR 1-14). The mechanism of their enantioselection, supported by the elution order of (S)-TR 13 and (R)-TR 13 and molecular modeling of the complex of the slower running (S)-TR 13 with CSP 1 is discussed. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12774294     DOI: 10.1002/chir.10200

Source DB:  PubMed          Journal:  Chirality        ISSN: 0899-0042            Impact factor:   2.437


  3 in total

1.  Enantioselective synthesis of SNAP-7941: chiral dihydropyrimidone inhibitor of MCH1-R.

Authors:  Jennifer M Goss; Scott E Schaus
Journal:  J Org Chem       Date:  2008-09-04       Impact factor: 4.354

2.  An efficacious protocol for C-4 substituted 3,4-dihydropyrimidinones. Synthesis and calcium channel binding studies.

Authors:  Kamaljit Singh; Divya Arora; Danielle Falkowski; Qingxin Liu; Robert S Moreland
Journal:  European J Org Chem       Date:  2009-07-01

3.  Resorcinol-, catechol- and saligenin-based bronchodilating β2-agonists as inhibitors of human cholinesterase activity.

Authors:  Anita Bosak; Anamarija Knežević; Ivana Gazić Smilović; Goran Šinko; Zrinka Kovarik
Journal:  J Enzyme Inhib Med Chem       Date:  2017-12       Impact factor: 5.051

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.